GYRE (Gyre Therapeutics) EBIT per Share : $0.16 (TTM As of Dec. 2024)

View and export this data going back to 2023. Start your Free Trial

What is Gyre Therapeutics EBIT per Share?

Gyre Therapeutics's EBIT per Share for the three months ended in Dec. 2024 was $0.01. Its EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2024 was $0.16.

During the past 12 months, the average EBIT per Share Growth Rate of Gyre Therapeutics was -45.50% per year. During the past 3 years, the average EBIT per Share Growth Rate was -26.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Gyre Therapeutics's EBIT per Share or its related term are showing as below:

GYRE' s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -26 Med: -26 Max: -26
Current: -26

During the past 4 years, the highest 3-Year average EBIT per Share Growth Rate of Gyre Therapeutics was -26.00% per year. The lowest was -26.00% per year. And the median was -26.00% per year.

GYRE's 3-Year EBIT Growth Rate is ranked worse than
82.65% of 1228 companies
in the Biotechnology industry
Industry Median: 5.9 vs GYRE: -26.00

Gyre Therapeutics's EBIT for the three months ended in Dec. 2024 was $0.7 Mil.

Gyre Therapeutics EBIT per Share Historical Data

The historical data trend for Gyre Therapeutics's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gyre Therapeutics EBIT per Share Chart

Gyre Therapeutics Annual Data

Trend

Dec21

Dec22

Dec23

Dec24

EBIT per Share

0.39

0.12

0.29

0.16

Gyre Therapeutics Quarterly Data
	Dec21	Mar22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
EBIT per Share	Get a 7-Day Free Trial						-0.07	0.08	0.03	0.04	0.01

Gyre Therapeutics EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Gyre Therapeutics's EBIT per Share for the fiscal year that ended in Dec. 2024 is calculated as

	EBIT per Share		(A: Dec. 2024 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	16.229	/	102.294
=	0.16

Gyre Therapeutics's EBIT per Share for the quarter that ended in Dec. 2024 is calculated as

	EBIT per Share		(Q: Dec. 2024 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	0.663	/	101.657
=	0.01

EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.16

Gyre Therapeutics (NAS:GYRE) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

Gyre Therapeutics EBIT per Share Related Terms

Thank you for viewing the detailed overview of Gyre Therapeutics's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Gyre Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Gyre Therapeutics Inc (NAS:GYRE) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

L9S:Germany

Address

12770 High Bluff Drive, Suite 150, San Diego, CA, USA, 92130

Website

https://www.gyretx.com

Gyre Therapeutics Inc is a commercial-stage pharmaceutical company developing and commercializing small-molecule anti-inflammatory and anti-fibrotic drugs targeting organ diseases, focusing specifically on organ fibrosis. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.